Nasdaq auph.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ...Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation – AUPH March 18, 2022 13:00 ET | Source: The Rosen ...Aldeyra Therapeutics Inc (NASDAQ:ALDX) has a beta value of 1.43 and has seen 0.58 million shares traded in the recent trading session. The company, currently valued at $177.64M, closed the recent trade at $3.02 per share which meant it gained $0.16 on the day or 5.59% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and has …Find the latest dividend history for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ...Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

Get the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

AUPH Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $14.20 with a high forecast of $15.00 and a low forecast of $13.00. The average price target represents a 71.29% change from the last price of $8.29.Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ...Oct 30, 2023 · We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ... Nov 22, 2021 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

Jul 18, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...

About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held ...The new research reports from Market Source Research, available for free download at the links above, examine Haverty Furniture Companies, Inc. (NYSE:HVT), BLACKLINE INC (NASDAQ:BL), MagnaChip ...Ocular Therapeutix Inc (NASDAQ:OCUL) has a beta value of 0.88 and has seen 1.29 million shares traded in the recent trading session. The company, currently valued at $262.48M, closed the recent trade at $3.31 per share which meant it gained $0.63 on the day or 23.32% during that session. ... (NASDAQ:AUPH) has a beta value of 1.39 and …AUPH Aurinia Pharmaceuticals Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update ...

In trading on Monday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $8.86 per share. By ...See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. AUPH's current price target is …Which Aurinia Pharmaceuticals insiders have been selling company stock? The following insiders have sold AUPH shares in the last 24 months: David R.W. Jayne ($98,333.58), Joseph M Miller ($100,986.24), Joseph P Hagan ($2,877.76), Peter Greenleaf ($292,785.00), and Stephen P Robertson ($173,453.88). How much insider selling is …Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. …A. Aurinia Pharmaceuticals ( AUPH) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 2, 2023 for Q3 and the Actual Revenue was $54 ...

Home AUPH • NASDAQ Aurinia Pharmaceuticals Inc Follow Share $9.06 After Hours: $9.03 (0.33%) -0.030 Closed: Dec 1, 7:57:38 PM GMT-5 · USD · NASDAQ · Disclaimer search …Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc ...

Perusahaan melaporkan laba per saham sebesar $-0,09 dan pendapatan sebesar $40,8M. Survei EPS dari analis Investing.com diharapkan sesuai perkiraan yang dirilis sebesar $-0,17 dengan laba $38,44M. Untuk tahun ini, saham Aurinia Pharma naik 65%, unggul kuat Nasdaq yang naik 24% dalam setahun hingga hari ini.Aurinia Pharmaceuticals (NASDAQ: AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (NASDAQ: BIIB) could potentially look to target the company. Aurinia ( AUPH ...Dr_Microbe. This article is a follow-up to my previous coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) and as such may run a little shorter than earlier ones.In particular, today, I'd like to ...AUPH: Get the latest Aurinia Pharmaceuticals stock price and detailed information including AUPH news, historical charts and realtime prices. Indices Commodities Currencies StocksEarnings vs Market: AUPH is forecast to become profitable over the next 3 years, which is considered above average market growth. High Growth Earnings: AUPH …Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus Revenue ...

The new research reports from Fundamental Markets, available for free download at the links above, examine Shinhan Financial Group Co Ltd (NYSE:SHG), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH ...

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...Dec 4, 2023 · Avid Bioservices Inc (NASDAQ:CDMO)’s Major holders. Insiders own 0.82% of the company shares, while shares held by institutions stand at 108.12% with a share float percentage of 109.02%. Investors are also buoyed by the number of investors in a company, with Avid Bioservices Inc having a total of 253 institutions that hold shares in the company. Home AUPH • NASDAQ Aurinia Pharmaceuticals Inc Follow Share $9.06 After Hours: $9.03 (0.33%) -0.030 Closed: Dec 1, 7:57:38 PM GMT-5 · USD · NASDAQ · Disclaimer search …2 нояб. 2023 г. ... Aurinia Pharmaceuticals (AUPH) reported better-than-expected Q3 2023 financials on Thursday driven by its lupus nephritis therapy Lupkynis.The fact that multiple Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...Dec 4, 2023 · December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session. Sep 29, 2022 · Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. The share price has slid 66% in that time. Nov 24, 2021 · Every investor in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ... Dec 4, 2023 · The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ... Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...

July 15, 2020 at 10:15 AM · 4 min read. Steven Cohen ( Trades, Portfolio ), head of Point72 Asset Management, disclosed this week his firm upped its stake in Otonomy Inc. (NASDAQ:OTIC) by 1,354. ...Cramer said Aurinia Pharmaceuticals Inc. AUPH is a Canadian company that "I don’t really have a lot of confidence in, and I’m not recommending any companies that are losing money hand over ...Shares of the autoimmune disease specialist Aurinia Pharmaceuticals ( AUPH -1.04%) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price cratered by more ...Instagram:https://instagram. top dividend reitsnvdia target pricegphof stock forecasthow to etrade for beginners Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, … how to endorse a checlbrk.a share price Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. On the bright side, the stock is actually up 50% ibm stock buy or sell Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held ...Aurinia Pharmaceuticals AUPH rose almost 5.8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. AUPH will consider a range of options ...